In Part 2 of our ACR Convergence Highlights coverage, Peter C Taylor (University of Oxford, Oxford, UK) discusses the results of an exploratory study into the association of Hydroxychloroquine (HCQ) use and the development of Non-Alcoholic Fatty Liver Disease (NAFLD) in patients with RA.
The full abstract ‘Association of Hydroxychloroquine Use with Development of Non-Alcoholic Fatty Liver Disease in Rheumatoid Arthritis’ was presented at ACR Convergence 2020.
Other highlights in this series include PART 1, PART 3 and PART 4.
Disclosures: Peter C Taylor reports receiving: Research grants from Celgene, Galapagos, Gilead and Lilly; and consultation fees from AbbVie, BMS, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
